bay-i 9139 has been researched along with oxiconazole in 2 studies
| Studies (bay-i 9139) | Trials (bay-i 9139) | Recent Studies (post-2010) (bay-i 9139) | Studies (oxiconazole) | Trials (oxiconazole) | Recent Studies (post-2010) (oxiconazole) |
|---|---|---|---|---|---|
| 13 | 0 | 0 | 72 | 18 | 14 |
| Protein | Taxonomy | bay-i 9139 (IC50) | oxiconazole (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.9103 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.09 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 4.0827 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.6345 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 4.7364 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.7449 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.6345 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.6499 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 4.1645 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 5.5774 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 4.531 | |
| Substance-K receptor | Homo sapiens (human) | 3.2218 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 4.1361 | |
| Acetylcholinesterase | Homo sapiens (human) | 4.6465 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.9103 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.6174 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 4.163 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 5.5774 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.8001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.04 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.9937 | |
| Delta-type opioid receptor | Homo sapiens (human) | 5.3081 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 4.6064 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.6345 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.6555 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cauwenbergh, G | 1 |
| Abbott, AB; Odds, FC; Webster, CE | 1 |
2 other study(ies) available for bay-i 9139 and oxiconazole
| Article | Year |
|---|---|
New and prospective developments in antifungal drugs.
Topics: Administration, Oral; Administration, Topical; Allylamine; Antifungal Agents; Clotrimazole; Dermatomycoses; Drug Compounding; Humans; Imidazoles; Itraconazole; Ketoconazole; Miconazole; Naphthalenes; Terbinafine; Triazoles | 1986 |
Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents.
Topics: Antifungal Agents; Aspergillus; Candida; Clotrimazole; Econazole; Imidazoles; In Vitro Techniques; Itraconazole; Ketoconazole; Miconazole; Morpholines; Triazoles | 1984 |